reports
Calithera Biosciences Announces Update on Complete Liquidation and Dis...
Calithera Biosciences Announces Update on Complete Liquidation and Dissolution Cancels Special Meeting of Stockholders SOUTH SAN FRANCISCO, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: “CALA”). Calithera Biosciences, Inc. (the “Company”) announced that it was unable to achieve a quorum of stockholders at its special meeting of stockholders scheduled to be held on June 29, 2023 (the “Special Meeting”), for the purpose of approving the Company’s Plan of Complete Liquidation and Dissolution. In January 2023, the Company announced its intention to commence an ...
Calithera Biosciences Announces Update on Complete Liquidation and Dis...
Calithera Biosciences Announces Update on Complete Liquidation and Dissolution Special Meeting to be Held on or about June 29, 2023 with a Record Date of May 25, 2023 SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: CALA) (the “Company”) announced that it intends to hold a special meeting of stockholders on or about June 29, 2023 (the “Special Meeting”), for the purpose of approving the Company’s Plan of Complete Liquidation and Dissolution (the “Plan of Dissolution”). In January 2023, the Company announced its intention to commence an or...
Calithera Biosciences Inc: 1 director
A director at Calithera Biosciences Inc sold 121,333 shares at 0.386USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Calithera Biosciences Announces Board Approval of Complete Liquidation...
Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic alternatives, that it is in the best interests of its shareholders to dissolve the Company and liquidate its assets, following an orderly wind down of the company’s operations. In order to reduce costs and in connection with the planned dissolution, Calithera is discontinuing all clinica...
Calithera Biosciences Reports Third Quarter 2022 Financial Results and...
Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update -- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, November 14, 2022 -- SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the third quarter ended September 30, 2022. “Earlier in the fourth quarter, we were very pleased to announce that we received FDA Fast Track designation for sapanisertib. This designation facilitates mo...
Calithera Biosciences to Report Third Quarter 2022 Financial Results o...
Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022 SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company’s third quarter 2022 financial results will be released on Monday, November 14, 2022. Company management will host a conference call on Monday, November 14, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. Participants wh...
Calithera Receives FDA Fast Track Designation for Sapanisertib for the...
Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer Enrollment ongoing in Phase 2 study evaluating sapanisertib, a dual mTORC1/2 inhibitor, in patients with squamous non-small cell lung cancer harboring a NRF2 mutation SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation for the company’s investigational mTOR...
Calithera to Present at the H.C. Wainwright 24th Annual Global Investm...
Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14 both virtually and in New York, NY. The presentation will be available for on-demand viewing starting Monday, September 12,...
Calithera Biosciences Reports Second Quarter 2022 Financial Results an...
Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights -- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, August 15, 2022 -- SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022. “We continue to deliver on our commitment to efficiently advance our clinical programs, successfully initiating two new clinical trials and sharing program updat...
Calithera Biosciences to Report Second Quarter 2022 Financial Results ...
Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022 SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company’s second quarter 2022 financial results will be released on Monday, August 15, 2022. Company management will host a conference call on Monday, August 15, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. Participants who wi...
Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib ...
Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences -- Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma -- -- First data from phase 1 investigator-sponsored clinical study of TORC 1/2 inhibitor sapanisertib in combination with telaglenastat in patients with non-small cell lung cancer -- SOUTH SAN FRANCISCO, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, ...
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clin...
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma -- Novel biomarker will be used to identify patients in genetically defined subgroup associated with poorer outcomes -- Study will evaluate SYK inhibitor both in patients with wild-type disease and those with tumors that harbor MYD88 or CD79b mutations SOUTH SAN FRANCISCO, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, annou...
Calithera Biosciences Announces 1-for-20 Reverse Stock Split
Calithera Biosciences Announces 1-for-20 Reverse Stock Split SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-20 reverse stock split, effective as of 5:00 p.m. Eastern Time today. The reverse stock split was effected by Calithera in accordance with the authorization, and within the split ratio range, adopted by Calithera stockholders a...
Calithera to Present at the H.C. Wainwright Global Investment Conferen...
Calithera to Present at the H.C. Wainwright Global Investment Conference SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-25 both virtually and in Miami, FL. The presentation will be available for on-demand viewing starting Tuesday, May 24 at 7:00 a.m. Eastern Time, and can be acce...
Calithera Biosciences Reports First Quarter 2022 Financial Results and...
Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights -- Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Tuesday, May 10, 2022 -- SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the first quarter ended March 31, 2022. “We made significant headway in the transfer of mivavotinib and sapanisertib materials to Calithera during the first quarter and are well into ...
Calithera Biosciences to Report First Quarter 2022 Financial Results o...
Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022 SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company’s first quarter 2022 financial results will be released on Tuesday, May 10, 2022. Company management will host a conference call on Tuesday, May 10, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. The press release...
Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financ...
Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Thursday, March 31, 2022 SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2021. “In 2021, we made significant progress in streamlining our clinical development programs, prioritizing our resources, and e...
Calithera Biosciences, Inc. Prices $10.0 Million Underwritten Public O...
Calithera Biosciences, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 18,518,519 shares of its common stock at a price to the public of $0.54 per share. Each share of common stock is accompanied by a warrant to purchase one share of common stock at an exercise price of $0....
Calithera Biosciences, Inc. Announces Commencement of Underwritten Pub...
Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock, warrants to purchase shares of its common stock, and pre-funded warrants in an underwritten public offering. All of the shares of common stock, warrants and pre-funded warrants are being offered by Calithera....
Calithera Biosciences to Report Fourth Quarter and Full Year 2021 Fina...
Calithera Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 31, 2022 SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company’s fourth quarter and full year 2021 financial results will be released on Thursday, March 31, 2022. Company management will host a conference call on Thursday, March 31, 2021 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent cor...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.